Prevention of risks associated with inappropriate use/unnecessary consumption of medicines

[1]  M. Lapeyre-Mestre,et al.  Early Detection of Prescription Drug Abuse Using Doctor Shopping Monitoring From Claims Databases: Illustration From the Experience of the French Addictovigilance Network , 2021, Frontiers in Psychiatry.

[2]  J. Emmerich,et al.  Collaboration Between Health-Care Professionals, Patients, and National Competent Authorities Is Crucial for Prevention of Health Risks Linked to the Inappropriate Use of Drugs: A Position Paper of the ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé) , 2021, Frontiers in Pharmacology.

[3]  M. Roustit,et al.  Reported Adverse Drug Reactions Associated With the Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic , 2021, Annals of Internal Medicine.

[4]  K. Niburski,et al.  Impact of Trump's Promotion of Unproven COVID-19 Treatments and Subsequent Internet Trends: Observational Study , 2020, Journal of Medical Internet Research.

[5]  M. Arnaud,et al.  Medicine misuse: A systematic review and proposed hierarchical terminology , 2020, British journal of clinical pharmacology.

[6]  R. Bordet.  Is the drug a scientific, social or political object? , 2020, Therapies.

[7]  M. Mallaret,et al.  [Safety signal detection by the French Addictovigilance Network: Innovative methods of investigation, examples and usefulness for public health]. , 2019, Therapie.

[8]  P. Jolliet,et al.  French national health insurance database analysis and field study focusing on the impact of secure prescription pads on zolpidem consumption and sedative drug misuse: ZORRO study protocol , 2019, BMJ Open.

[9]  M. Lapeyre-Mestre,et al.  Interest of large electronic health care databases in addictovigilance: Lessons from 15 years of pharmacoepidemiological contribution. , 2019, Therapie.

[10]  B. Bégaud,et al.  [Psychotropic drug use and correspondence with psychiatric diagnoses in the mental health in the general population survey]. , 2008, L'Encephale.

[11]  B. Giraudeau,et al.  Avoidability of Adverse Drug Reactions Spontaneously Reported to a French Regional Drug Monitoring Centre , 2009, Drug safety.

[12]  R. Nelson,et al.  Good Pharmacovigilance Practices , 2002, Drug safety.

[13]  O. Maisonneuve.  La consommation des benzodiazépines en France , 1991 .